Introduction
To prevent and improve age-related brain dysfunction has become an important and emergent issue with the rise in life expectancy. Actually, cognitive and locomotor function deficit are hallmarks not only of pathological aging but also of healthy aging processes, which may be due to neuroinflammation in the hippocampus (Boehme et al., 2014; Babcock et al., 2015) , reduced synaptic plasticity and neurogenesis (Cutuli et al., 2014; Gebara et al., 2015) , etc. Neuroinflammation, including increase in proinflammatory cytokines, as well as microglia and astrocyte activation, has been reported to contribute to the cognitive and behavioral impairment induced by radiation, Alzheimer disease, Parkinson disease, etc. (Jenrow et al., 2013; Kim et al., 2015; Park et al., 2015) . Thus, manipulations aimed at inhibiting neuroinflammation response represent a promising approach for alleviating age-related cognitive impairment as well as behavioral deterioration.
Bone marrow mesenchymal stem cells (BMMSCs), multipotent progenitor cells with self-renewal ability and the capacity to differentiate several distinct mesenchymal lineages, are widely used in several central nervous system (CNS) diseases, such as cortical ischemia (Franco et al., 2012) , spinal cord injury (Han et al., 2014) , and spinocerebellar ataxia (Chang et al., 2011) . Numerous studies showed that BM-MSCs transplantation could reduce inflammation, induce repair of nerve cells, and restore nerve function by secreting neurotrophic factors and antiinflammatory cytokines (Zhou et al., 2009; Pastor et al., 2012; Han et al., 2014) , therefore supporting beneficial outcomes when BM-MSCs were transplanted into a variety of disease models involving inflammation.
However, these studies did not address whether it could inhibit neuroinflammation response and delayed functional deterioration in aged mice. Therefore, in the present study, we examined the effects of BM-MSCs on the activation of microglia and astrocyte expression, as well as on inflammatory mediators in the hippocampus in aged C57BL/6J mice. The effects of cognitive and locomotor function deterioration were also investigated.
Materials and methods

Animals and groups
Male aged C57BL/6J mice (24 months old at the onset of the study) were used (Shanghai Slyke Laboratory Animal Limited Corporation, Certificate No. SCXK 2012-0002, China) . The animals were group-housed (3-4 mice/ cage) under a 12:12 h light-dark cycle with controlled temperature of 22 ± 1 °C and humidity of 50 ± 10%. Food and water were provided ad libitum. The animals were divided in 3 groups: (1) normal aged mice treated with nothing (group name: normal; n = 12); (2) mice treated with saline 2 µL/mouse (group name: saline; n = 12); (3) mice treated with BM-MSCs cultures 2 µL/mouse (1 × 10 8 cells) (group name: BM-MSCs; n = 12). All experiments were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals.
Experimental procedures
The mice were tested in the following validated behavioral tasks at 7 and 42 days after intraventricular injection with saline or BM-MSCs: locomotor activity, novel object recognition (NOR) test, and spatial Y-maze (SYM) test. After behavioral tests at 42 days after transplantation, the animals (8 mice in each group) were transcardially perfused followed with 10% chloral hydrate (4 g/kg). Then their brains were removed and cut into 10-µm coronal sections on a cryomicrotome (CM1900, Leica, Germany) to perform an immunohistochemistry evaluation. The hippocampus and cortex of the other mice were separated to detect content of IL-1α, IL-1β, and TNF-α by ELISA.
BM-MSCs culture and transplantation
The BM-MSCs line originated from a C57BL/6J mouse (MUBMX-01001) and culture media were both obtained from Cyagen Biosciences Company, Guangzhou. The medium was replaced every other day and the cell line was passaged once every about 5 days. The mice were anesthetized intraperitoneally with 10% chloral hydrate (4 g/kg) and placed into a stereotaxic apparatus (Benchmark 463001, Myneurolab Company, USA). The right lateral ventricle was targeted at the following coordinates: from bregma -0.22-mm anterior, 1.0-mm lateral, 2.6-mm depth according to mouse brain stereotaxic atlas. Next, 2 µL of BM-MSCs (about 1× 10 8 cells) or saline was injected at a rate of 0.4 µL/min. After injection, the syringe was left in place for an additional 5 min and gradually removed. The surface of the skull was covered with dental glue and the scalp was sutured and disinfected with 75% ethanol. Finally, the mice were warmed and returned to their cages after complete reawakening.
Behavioral tests 2.4.1. SYM test
The Y-maze apparatus (Huaibei ZhengHua Biological Instrument Equipment Co., Ltd, China) consisted of three identical arms with a 120° angle between adjacent arms. The three arms were designated as follows: start arm and familiar arm always open, and novel arm blocked during the first trial and opened during the second trial. The SYM test apparatus consisted of two trials separated by a 4-h intertrial interval. During the first trial (training phase), the mouse was allowed to explore the start and familiar arms with the novel arm being blocked, and this lasted 10 min. During the second trial (retention phase), the mouse was allowed to freely explore all three arms, and this lasted 5 min. The trials were recorded and analyzed by a video analyzer (Ethovision XT, Noldus, Netherlands). Total time spent in the novel arm and the percentage of alteration in the retention phase were analyzed. Spontaneous alteration is considered when a mouse visits a new arm but does not return to one of the previously visited two arms. The percentage of alteration = [number of spontaneous alteration/(number of entries -2)] × 100 (Wahl et al., 1992) .
NOR test
The NOR test is a nonrewarded, ethologically relevant paradigm based on the spontaneous exploratory behavior of rodents that measures recognition memory. It is widely used in a variety of animal models of human conditions where cognition is impaired. As described previously (Kajitani et al., 2010) , the task consisted of three trials: habituation (to minimize the effects of stress), pretest (to explore two identical objects), and test (to explore one familiar object and one novel object). During habituation, mice were introduced in the empty chamber and left to freely explore it for 10 min. Afterwards, they were put in their home cages for 5 min, during which two identical objects (familiar object: cubic crude wood 4 cm in diameter) were placed in two opposite corners of the chamber. During the pretest, mice were placed in the center of the chamber oriented toward the objects and allowed to explore the objects for 5 min. After a 1.5-h intertrial interval, mice were placed again for 5 min in the chamber, where one of the familiar objects was replaced by a novel one (novel object: cylindrical crude wood 4 cm in diameter and height). The duration time, which the mice took to explore the familiar and novel object, was recorded. Each recognition trial was videotaped and scored for time spent in the zone surrounding each object using Ethovision software (EthoVision XT; Noldus Information Technology, Netherlands). Discrimination ratio and discrimination index were calculated by taking the difference between the times spent exploring the novel and familiar objects and this was divided by the time spent exploring both objects during the pretest and test phase. Discrimination ratio = [N / (N + F)] × 100%), and discrimination index = [(N -F) / (N + F)] × 100%. (N: the time to explore a novel object, F: the time to explore a familiar object). Exploration was defined when the distance between the mouse's nose and the object is ≤ 2 cm when it faces the object.
Locomotor activity test
The locomotor activity test was carried as described previously (Schmidt et al., 2008 ) and recorded using a Spontaneous Activity Video Analysis System (JLBehv-LAG-4, Shanghai Jiliang Software Technology Co., Ltd. China). Each mouse was placed gently in the center of the chamber (40 × 40 × 35 cm). The locomotor tracks were continuously recorded by a video camera for 1 h and analyzed. The following parameters were determined: (a) total traveled distance (m); (b) mean traveled velocity (cm/s) within 1 h, which reflected the spontaneous activity of animals. After each test session, the enclosures were thoroughly cleaned with 70% ethanol solution.
Immunohistochemical evaluation
First, 10-µm sections were treated with 0.3% Triton-X 100 for 1 h, then 0.3% H 2 O 2 in methanol for 30 min, hydrated gradually to distilled water, and incubated for 1 h with 5% BSA to block nonspecific immune reactions. Afterwards, sections were incubated overnight at 4 °C with polyclonal rabbit anti-Iba1 (1:400, Wako Pure Chemical Industries, Ltd., Japan) and -GFAP antibodies (1:200, Wuhan Boster Biological Engineering Co., China). The next day, after washing, the sections were incubated with biotinylated goat anti-rabbit IgG (1:200, Abcam, USA) for 1 h following with incubation with avidin-biotin-peroxidase complex (1:200, Wuhan Boster Biological Engineering Co., China) for 2 h. Finally, the sections were exposed for 0.5-2 min to 0.01% 3,3'-diaminobenzidine (Wuhan Boster Biological Engineering Co., China) followed with hematoxylin counterstaining for 0.5-1 min. Normal goat serum was used instead of the primary antibody in the control sections. The morphological change and the expression number of microglia and astrocyte in hippocampal CA1 region and dentate gyrus (DG) were observed.
ELISA detection
At 42 days after BM-MSCs transplantation, 4 mice in each group were decapitated quickly. The hippocampus and cortex were separated on ice, and then sonicated to obtain tissue homogenates. After removing particulars by centrifugation (2000 × g, 4 °C, 20 min), the assay was immediately performed. Content of IL-1α, IL-1β, and TNF-α were measured using the respective ELISA kit (Shanghai Elisa Biotech Co., Ltd, China) according to the manufacturer's instructions. Finally, optical density was determined (absorbance at 450 nm) on a plate reader.
Statistical analysis
The data are expressed as mean ± standard error (SEM). Compared with the normal or saline group, the effects of BM-MSCs transplantation were performed using one-way ANOVA with Bonferroni post hoc test using SPSS 16.0 for Windows. The data of the NOR test in the test were compared with those in the pretest using an independent t-test. P < 0.05 was considered to be statistically significant.
Results
Effects of BM-MSCs transplantation on the SYM test in aged C57BL/6J mice
Compared with the normal group, treatment with saline did not change time in the novel arm or percentage of alteration in the SYM test at 7 and 42 days after transplantation. Compared to the saline group ( Figures  1a and 1b) , BM-MSCs transplantation not only increased time in the novel arm but also percentage of alteration at 7 and 42 days. However, there was no difference between the BM-MSCs group and the normal group at 7 days after transplantation (Figure 1a) .
Effects of BM-MSCs transplantation on the NOR test in aged C57BL/6J mice
At day 7 after transplantation, there was no difference in the discrimination ratio or discrimination index among all groups in the NOR test (data not shown). However, at day 42 after transplantation, treatment with saline still did not change the discrimination ratio (Figure 2a ) or discrimination index (Figure 2b ) compared with the normal group. BM-MSCs transplantation, on the other hand, increased the discrimination ratio (Figure 2a ) and discrimination index (Figure 2b ) in the NOR test when compared with the normal or saline group. There was no significant difference in discrimination ratio (Figure 2a ) or discrimination index (Figure 2b) between the test and pretest in the normal and saline groups. However, BMMSCs treatment increased the discrimination ratio ( Figure  2a ) and discrimination index (Figure 2b ) in the test.
Percentage of alteration (%)
Effects of BM-MSCs transplantation on the locomotor activity test in aged C57BL/6J mice
At 7 days after transplantation, in the saline group and BMMSCs group traveled total distance ( Figure 3a ) and mean velocity ( Figure 3b ) within 1 h were not affected in the locomotor activity test compared with the normal group. However, at 42 days after transplantation, BM-MSCs transplantation increased traveled total distance ( Figure  3a ) and mean velocity (Figure 3b ) within 1 h. There was no difference between the saline group and the normal group at 42 days after transplantation (Figures 3a and 3b) .
BM-MSCs transplantation inhibited the expression of microglia in the hippocampus CA1 region and DG
We assessed microglia activation by detection of the expression of Iba-1 by immunohistochemistry. Iba-1 can detect both resting and activated microglia, while resting microglia are activated and transformed from a ramified to an amoeboid morphology in the aged brain. As shown in Figure 4a , all groups exhibited activated microglia, but few were expressed in BM-MSCs-treated mice. The number of activated microglia in the BM-MSCs group was decreased compared with the normal and saline groups in both the hippocampus CA1 region and DG ( Figure. Saline treatment did not change the number of microglia expressed (Figure 4b ).
BM-MSCs transplantation inhibited the expression of astrocytes in hippocampus CA1 and DG
GFAP positive cells were expressed in the hippocampus CA1 region and DG at 42 days after transplantation in all groups (Figure 5a ). Injection with saline had no effect on astrocyte number (Figure 5b ), but BM-MSCs treatment inhibited the expression of astrocytes in both the hippocampus CA1 region and DG (Figure 5b ).
BM-MSCs transplantation decreased the expression of IL-α and IL-β in the hippocampus
Compared with the normal group, the saline group did not have changed expression of IL-α (Figure 6a ), IL-β (Figure   6b ), or TNF-α (Figure 6c ) in the hippocampus or cortex. BM-MSCs transplantation decreased IL-α ( Figure 6a ) and IL-β (Figure 6b ) expression in the hippocampus but not in the cortex. However, BM-MSCs transplantation had no effect on TNF-α expression in the hippocampus or cortex (Figure 6c ).
Discussion
In this work we have shown that BM-MSCs transplantation is capable of delaying cognitive and locomotor function deterioration in aged mice. Moreover, it inhibited the activation of microglia and astrocytes, followed by a decrease in proinflammatory factors. Our research found there was no difference in mortality among the groups (data not shown). Some papers reported that BM-MSCs significantly prolonged the graft survival time of other organs, such as the skin and heart (Hu et al., 2013; Wu et al., 2013; Zhang et al., 2013) , but no reports showed higher lifetime in vivo. Our results also did not verify whether it can lengthen lifetime in vivo yet.
BM-MSCs are relatively easy to obtain, require minimum manipulation, and can be extracted and rapidly reimplanted into the region of interest with different medications. At present, it was administrated by intraventricular, intravenous, and intraperitoneal injection to treat various CNS diseases (Yamawaki-Ogata et al., 2014; Zhu et al., 2014) . However, compared with intravenous or intraperitoneal injection, intraventricular injection can make the cells reach the brain tissue directly, and avoid the shielding effect of the blood-brain barrier and peripheral organs. Thereby the dosage is reduced and the success rate of transplantation increased (Kopen et al., 1999) .
Another point of this research is the effect of BMMSCs transplantation on microglia and astrocyte expression in the hippocampal CA1 region and DG. In the aged brain, microglia is primed to be activated. Moreover, astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype (Salminen et al., 2011; Norden and Godbout, 2013) . Microglia are the primary immunocompetent cells in brain tissue and microglia-mediated inflammation is associated with the pathogenesis of various neuronal disorders and a healthy aging brain, which are major cellular sources of TNF and IL-1 family of cytokines, including IL-1α and IL-1β (Boehme et al., 2014; Babcock et al., 2015) . Several studies suggest that overactivated microglia is a detrimental factor in CNS diseases (Hamby et al., 2007) , but other experimental evidence showed inhibiting overactivated microglia exerted a protective effect in CNS diseases (Neumann et al., 2008) . Furthermore, astrocyte activation, associated with the release of proinflammatory factors IL-1β, IL-6, and TNF-α, is also a hallmark of multiple brain diseases (Kong et al., 2015) . According to Boehme et al. (2014) , astrocytic marker-GFAP and microglial marker-Iba1 significantly increased in the aged hippocampus. Therefore, our study was conducted for immunohistochemical analysis of the microglia marker Iba1, astrocyte marker GFAP, and quantification of inflammatory markers in the hippocampus to evaluate the effect of BM-MSCs transplantation on aged mice. The results showed BM-MSCs transplantation inhibited microglia and astrocyte activation, leading to reduced production of proinflammatory factors, including IL-1α and IL-1β, but without change in TNF-α, which was in accordance with the antiinflammatory properties of BMMSCs transplantation in other CNS diseases (Han et al., 2014; Liu et al., 2014) . Increased IL-1α and IL-1β have been described in many studies assessing the aged brain (Griffin et al., 2006; Henry et al., 2009) . TNF-α is released during the earliest stages of CNS injury (Ersahin et al., 2012) . Therefore, contradictory results have also been found for TNF-α in age-related diseases (Lanzrein et al., 1998; Griffin et al., 2006) , which may be related to the dysregulation of proinflammatory factors in the aged brain. In addition, our results found BM-MSCs transplantation had no effect on proinflammatory factors in the cortex. The cortex is a complex structure in the brain that includes frontal, temporal, parietal, occipital, and insular lobes. Each region has different effects on proinflammatory factors. In the future, to subdivide the cortex and detect the change in proinflammatory factors are essential. Furthermore, in our study, mice were tested in the following validated behavioral tasks tapping distinct hippocampal-dependent abilities: SYM test to assess spatial memory and NOR test to analyze novelty recognition memory, which are often used to assess learning and memory ability in CNS diseases (Rachmany et al., 2013; Huang et al., 2014) . Locomotor activity test in an open field is frequently used to evaluate basic behaviors used in psychological and pharmacological investigations (usually in rodents) (Zhang et al., 2006) . Aging was accompanied by a decline in learning and memory ability, which demonstrated in our results no difference between the test and pretest in the NOR test. However, in fact, discrimination ratio and discrimination index in the test increased in adult mice compared with the pretest (Kajitani et al., 2010; Saleem et al., 2014) . BMMSCs transplantation delayed cognitive deterioration, which manifested as increased time in the novel arm and percentage of alteration in the SYM test, and increased discrimination ratio and discrimination index in the NOR test. Furthermore, BM-MSCs treatment increased the traveled distance and velocity in the locomotor activity test, which indicated locomotor function improvement. The cognitive and locomotor function improvement may be related to decreased inflammatory responses in the hippocampus. Based on these results, intraventricular injection with BM-MSCs can inhibit the overactivation of microglia and astrocytes, followed by a reduction in proinflammatory factors in the hippocampus in aged C57BL/6J mice. As a result, it delayed cognitive and locomotor function deterioration. Therefore, BM-MSCs transplantation could provide a rationale for exploring the viability of using BMMSCs transplantation in cognitive deficit diseases.
